Inclusion Criteria:

          -  Males or females ≥ 18 years old (Parts 1 and 2A); males or females ≥ 16 years old
             (Part 2B)

          -  Willing and able to provide consent (and assent for patients between the ages of
             16-18)

          -  Part 1: Histologically or cytologically confirmed solid tumors or non-Hodgkin
             lymphoma, which have failed, are intolerant to or are considered ineligible for
             standard-of-care anti-cancer treatments

          -  Part 2A: Histologically or cytologically confirmed solid tumors which have failed, are
             intolerant to or are considered ineligible for standard-of-care anti-cancer
             treatments; documentation of MYC genomic amplification/overexpression is required

          -  Part 2B: Histologically or cytologically confirmed soft tissue sarcomas with defined
             transcription factor oncogenic drivers

          -  Access to a tumor sample for central laboratory testing

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1

          -  Evaluable or measurable disease, per Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1 for solid tumors or the Lugano Classification for non-Hodgkin lymphoma

          -  Adequate bone marrow and organ function

          -  Recovery from treatment-related toxicities from prior therapies to National Cancer
             Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade ≤ 1 or to
             baseline level

          -  Must agree to use highly effective birth control during the trial and for at least 3
             months after the last dose of study drug; female participants cannot be pregnant or
             breastfeeding

        Exclusion Criteria:

          -  Any other anti-cancer therapies including chemotherapy, immunotherapy, or hormonal
             therapy within 4 weeks or 5 half-lives (whichever is shorter)

          -  History of surgery (except for diagnostic purposes) or non-palliative radiotherapy
             within 4 weeks

          -  History of allogeneic transplantation within 6 months

          -  Active central nervous system (CNS) involvement by the underlying malignancy;
             previously treated CNS metastatic disease is permitted with magnetic resonance imaging
             (MRI) documentation of stable disease for at least 3 months prior to study start

          -  History of stroke or intracranial hemorrhage within ≤6 months

          -  Active infections requiring systemic antibiotic, antiviral or antifungal therapy

          -  Known active coronavirus disease 2019 (COVID-19)

          -  Clinically significant heart disease

          -  Uncontrolled hypertension

          -  Prolongation of QT interval at baseline

          -  Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection

          -  Significant concurrent, uncontrolled medical condition including, but not limited to,
             renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological,
             cerebral or psychiatric disease